The Cleveland Clinic Florida Research and Innovation Center (FRIC) is a cutting-edge research institute dedicated to advancing medicine and saving lives through groundbreaking research, discovery and innovation. Researchers work to expedite the timeline of translating basic science discovery to treatments that can extend human life and improve the efficiency of healthcare delivery. FRIC will develop next generation treatments for a broad scope of diseases that result life-threatening illnesses – improving healthcare in Florida and globally.

Our research focuses on emerging infectious diseases as well the role of the immune system in infectious disease and cancer. We aim to better understand the complex interactions between the body’s immune response to pathogens and cancer cells. Our work will translate to the development of new vaccines, anti-viral drugs and immunotherapies to advance treatments in the areas of cancer, neurosciences, infectious disease and heart disease.

Infectious Diseases

COVID-19, influenza, diseases caused by mosquito- or tick-borne viruses


Leukemia, prostate cancer, glioblastoma and virus-induced cancers

More than ever, research is critical to our understanding of infectious diseases and the development of treatment and vaccines. The Cleveland Clinic Florida Research and Innovation Center plays a key role in this global effort.

The FRIC complements and expands research currently underway at Cleveland Clinic’s five Florida hospitals, as well as Cleveland Clinic’s Lerner Research Institute in Cleveland, Ohio. Our facilities span approximately 100,000 sq. ft of dedicated research and support spaces, including state-of-the-art shared resource facilities in flow cytometry, imaging and bioinformatics.

Learn More

Cleveland Clinic researchers collaborate with international team to uncover how the body responds to life-threatening disease from herpes simplex virus 1

Researchers revealed novel genetic alterations and immune mechanisms in a child that was hospitalized with herpes encephalitis.

Read More


Cleveland Clinic Receives $7.9 Million Grant from NIH to Form Radiation Oncology-Biology Integration Network (ROBIN)

Precision cancer medicine is the goal of a new multidisciplinary study, led by Dr. Tim Chan, examining radiation therapy combined with targeted therapy

Read More


Florida Research and Innovation Center Team Discovers New Signal for Triggering Human Immune Response

Cytoskeleton disturbance is key in inducing immune response; multi-trigger immune system signaling holds implications for vaccines, therapeutics.

Read More


Cleveland Clinic Receives $2.9 Million for Additional Research on Emerging Tick-borne Virus Pathogen

Dr. Jae Jung will study the natural course of infection and viral reassortment of the emerging pathogen, Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV).

Read More


Cleveland Clinic Appoints Ted Ross, PhD, as Global Director of Vaccine Development

In this newly created role, he will lead the development of novel vaccine platforms for a variety of infectious diseases, including influenza, HIV and COVID-19.

Read More


Lerner-Developed Flow Cytometry Best Practices Lay Groundwork for Global Recommendations

Dr. Asosingh’s team developed new Shared Resource Laboratory (SRL) guidelines, including user consultations, to ensure experimental success and accuracy.

Read More


Researchers to Study if Non-Coding SARS-CoV-2 Genetic Material Can Offer Insights into New COVID-19 Therapies

Led by Dr. Fox, researchers from Cleveland and Florida will collaborate to investigate if certain regions of SARS-CoV-2 genetic material, called non-coding RNA, can be targeted to treat or prevent COVID-19 infection.

Read More


Dr. Michaela Gack Receives Prestigious NIH Director’s Pioneer Award

Dr. Gack has received a five-year, $5.6 million award as part of NIH’s High-Risk, High-Reward Research Program to study novel approaches to target viral pathogens, which may help inform the development of new antiviral therapies.

Read More


New Study From Cleveland Clinic Pathogens Researchers Points to Novel Drug Target for Treating COVID-19

Dr. Gack and other FRIC researchers discovered that a coronavirus enzyme blocks the activity of a previously undefined host immune response, suggesting therapeutics that inhibit the enzyme may help treat COVID-19.

Read More


$2.8M Grant Awarded to Develop Vaccine to Counter Emerging Tick-Borne Virus

The funds, the first to go to Cleveland Clinic’s new Center for Global and Emerging Pathogens, will support Dr. Jung’s work to test four vaccine candidates against the virus that causes severe fever with thrombocytopenia.

Read More


Cleveland Clinic Names Chair of Department of Cancer Biology

Jae Jung, PhD, a renowned expert in virus-induced cancers and immunology research, will lead Lerner Research Institute’s Department of Cancer Biology and will also serve as director of Cleveland Clinic’s Center for Global and Emerging Pathogens Research.

Read More


Cleveland Clinic Florida Opens Florida Research and Innovation Center

The new center, which will complement and expand research underway at Lerner Research Institute, will focus on research related to cancer and infectious diseases, including COVID-19 and immune system response.

Read More